文献速递医院感染防控细菌感染、耐药与抗菌药物

荷兰母亲百日咳疫苗接种对12月龄内婴儿免疫应答的影响:开放标签平行随机对照试验

Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2019-03-27

该开放标签平行随机对照试验在荷兰招募118名孕妇,比较孕期30-32周接种Tdap与产后48小时内接种对婴儿百日咳抗体应答的影响。

要点

  • 母亲孕期接种Tdap可提高婴儿3月龄时百日咳毒素抗体水平。
  • 母亲接种组婴儿基础免疫后百日咳抗体浓度显著低于对照组。
  • 母亲接种Tdap后未发现安全问题。

核心结论

  • 母亲孕期接种Tdap可提高婴儿3月龄时百日咳毒素抗体浓度,支持将婴儿首剂百日咳疫苗延迟至至少3月龄。
  • 母体抗体干扰会影响基础免疫和加强免疫后的抗体浓度,其临床后果尚待明确。

研究设计与样本

  • 开放标签、平行、随机对照试验,在荷兰36个助产士诊所招募18-40岁低妊娠并发症风险的孕妇。
  • 孕妇随机分配至孕期30-32周接种Tdap组(58人)或产后48小时内接种对照组(60人)。
  • 所有足月婴儿在3、5、11月龄接种六联疫苗和十价肺炎球菌疫苗,主要终点为3月龄时血清IgG百日咳毒素抗体浓度。

主要发现

  • 母亲接种组婴儿2月龄时百日咳毒素抗体也显著高于对照组。
  • 基础免疫后,母亲接种组婴儿在全部时间点的百日咳毒素、丝状血凝素和百日咳杆菌黏附素抗体浓度均显著低于对照组。
  • 母亲接种Tdap后未遇到安全问题。

临床怎么用

  • 孕期接种Tdap可提高新生儿至3月龄的百日咳抗体水平,支持考虑将婴儿首剂百日咳疫苗延迟至至少3月龄。
  • 需注意母体抗体干扰导致基础免疫后抗体浓度降低,临床后果需进一步评估。

局限性

  • 开放标签设计,参与者和临床试验人员未设盲。
  • 样本量较小,共118名孕妇。
  • 母体抗体干扰的临床后果尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination offers protection for neonates against clinical pertussis until primary vaccinations, but maternal antibodies also interfere with infants' immune responses to primary vaccinations. We investigated the effect of maternal Tdap vaccination on the pertussis antibody responses of infants starting primary vaccinations at age 3 months. METHODS: In an open-label, parallel, randomised, controlled trial, pregnant women aged 18-40 years with a low risk of pregnancy complications were recruited through independent midwives at 36 midwife clinics in the Netherlands and received Tdap vaccination either at 30-32 weeks of pregnancy (maternal Tdap group) or within 48 h after delivery (control group). All term-born infants were vaccinated with the diphtheria, tetanus, and pertussis-inactivated poliomyelitis-Haemophilus influenzae type B-hepatitis B six-in-one vaccine and a ten-valent pneumococcal vaccine at 3 months, 5 months, and 11 months. Randomisation was done using a number generator in a 1:1 ratio and with sealed envelopes. Participants and clinical trial staff were not masked, but laboratory technicians were unaware of study group assignments. The primary endpoint was serum IgG pertussis toxin antibody concentrations at age 3 months. Cord blood and infant blood samples were collected at age 2 months, 3 months, 6 months, 11 months, and 12 months. Analysis was done by modified intention to treat with all randomly assigned participants in case a laboratory result was available. This trial is registered with ClinicaltTrialsRegister.eu (EudraCT 2012-004006-9) and trialregister.nl (NTR number NTR4314). The trial is now closed to new participants. FINDINGS: Between Jan 16, 2014, and March 4, 2016, 118 pregnant women were enrolled into our study, with 58 in the maternal Tdap group and 60 in the control group. The geometric mean concentration (GMC) of pertussis toxin antibodies were higher in infants in the maternal Tdap group than in the control group infants at age 3 months (GMC ratio 16·6, 95% CI 10·9-25·2) and also significantly higher compared with control infants at age 2 months. After primary vaccinations, antibody concentrations for pertussis toxin, filamentous haemagglutinin, and pertactin were significantly lower at all timepoints in infants of the maternal Tdap group than in infants in the control group. No safety issues after maternal Tdap vaccination were encountered. INTERPRETATION: In view of the high pertussis toxin antibody concentrations at age 3 months, maternal vaccination supports a delay of the first pertussis vaccination in infants until at least age 3 months. Maternal antibody interference affects antibody concentrations after primary and booster vaccinations. The clinical consequences of this interference remain to be established. FUNDING: The Dutch Ministry of Health, Welfare, and Sport.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Barug D, Pronk I, van Houten MA, et al. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial. Lancet Infect Dis. 2019. PMID: 30938299. doi:10.1016/S1473-3099(18)30717-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。